Skip to main content
Top
Published in: Diabetologia 12/2018

01-12-2018 | Research Letter

Probiotic intervention in infancy is not associated with development of beta cell autoimmunity and type 1 diabetes

Authors: Erkki Savilahti, Taina Härkönen, Emma M. Savilahti, Kaarina Kukkonen, Mikael Kuitunen, Mikael Knip

Published in: Diabetologia | Issue 12/2018

Login to get access

Excerpt

To the Editor: The initiators of the autoimmune process in the pancreatic islets leading to type 1 diabetes remain enigmatic. The close association of pancreas with the immunologically highly active gut makes the latter, together with the intestinal microbiota, a prime suspect in the process. Duodenal specimens of individuals with type 1 diabetes have shown distinct inflammation, even in the absence of an HLA genotype compatible with coeliac disease [1]. Furthermore, several inflammatory markers have been shown to be type 1 diabetes-specific in duodenal samples from individuals with type 1 diabetes [2]. Changes in inflammatory markers were associated with alterations in the relative and absolute densities of bacteria in the duodenal specimens [2]. The analysis of microbiota in stool samples from individuals who later progressed to type 1 diabetes suggested that at the time of the appearance of diabetes-associated autoantibodies, the intestinal microbiota shows dysbiosis characterised by decreased bacterial diversity and reduced quantities of bacteria producing butyrate and lactate [3]. Related to the microbiota, exposure to bacterial lipopolysaccharide has been implicated to affect the training of the infant immune system either favouring an increased predisposition to immune-mediated diseases such as type 1 diabetes and allergy or providing relative resistance to such diseases, depending on the specific lipopolysaccharide concerned [4]. …
Literature
Metadata
Title
Probiotic intervention in infancy is not associated with development of beta cell autoimmunity and type 1 diabetes
Authors
Erkki Savilahti
Taina Härkönen
Emma M. Savilahti
Kaarina Kukkonen
Mikael Kuitunen
Mikael Knip
Publication date
01-12-2018
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 12/2018
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-018-4738-4

Other articles of this Issue 12/2018

Diabetologia 12/2018 Go to the issue

Up Front

Up Front

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine